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Why is this study important?
Stroke is the leading cause of sustained disability
worldwide. Contrary to popular belief, two thirds of stroke
mortality will occur in the developing world in patients less
than 70 years of age. Among those who survive a stroke or
TIA, the risk of recurrent stroke is very high. Thus, broad
interventions that decrease the risk of stroke are welcome in the
developing world.
Blood pressure had been recognized as an important
determinant of the risk of initial stroke in several studies which
had included both hypertensive as well as normotensive
patients.1,2 However, the association between hypertension and
stroke recurrence was not as clear from previous studies.
The aim of this particular study was to determine the
effects of a flexible blood pressure lowering regimen on the
risk of stroke recurrence and other major vascular events in
patients who had a history of stroke or Transient ischaemic
attack. The patients were recruited regardless of their entry
blood pressure levels.
Who were the participants?
The study was conducted in 172 centers from ten
countries. Most of these countries were European except China
and Japan (contributed a total of 2335 subjects) and Australia
and New Zealand (contributed 1110 subjects). There were no
South Asian patients. 
Patients were eligible if they had a history of stroke or
transient ischaemic attack within the previous 5 years and in
the opinion of the responsible physician, no clear indication or
contraindication to ACE inhibitor therapy. These patients were
recruited at a median time of 8 months after their stroke
regardless of their blood pressure level- such that the mean
blood pressure amongst those classified as hypertensive was
159/94 and non hypertensive was 136/79. Hypertension was
defined as a blood pressure of >160 systolic or >90 diastolic for
this study. 
A total of 7121 patients were entered into a four week
pre-randomization run-in period during which they received
open label perindopril. 1061 were ineligible or withdrew.
Eventually 6105 were randomized, 3544 to combination
therapy or double placebo and 2561 to perindopril alone or
placebo.
What was the intervention?
Intervention arm comprised a flexible regimen
based on perindopril 4 mg daily with or without
Indapamide 2.5 mg daily. The decision to use a
combination was left to the discretion of the treating
physician. In the placebo arm the participants received
either single placebo identical to perindopril or a double
placebo similar to perindopril and Indapamide. A total of
3051 patients were randomized to active treatment, of these
1770 received combination therapy and 1281 got single
agent. In the placebo arm, 1774 were randomized to double
placebo, and 1280 to single placebo.
Patients were followed up for an average of four years
after randomization. In the first year they were seen on five
occasions, and then six monthly thereafter. At these visits,
information was collected regarding adherence to treatment,
Blood pressure, cognitive function, disability, occurrence of
major clinical events and tolerability of the study treatment.
What was the outcome?
Blood pressure was reduced by an overall average of
9.0/4.0 mm Hg in those who received active treatment
compared to those assigned placebo and this difference was
maintained throughout the follow-up period. Also those who
received double therapy had a greater reduction compared to
single agent (12·3/5·0 mm Hg vs. 4·9/2·8 mm Hg).
Ten percent of patients in the active group and 14% in
the placebo group had a recurrent stroke during the follow-up
period which translated into a relative risk reduction of 28%
[95% CI 17-38%; p<0.0001]. This benefit was accrued over all
stroke subtypes and was maximal in patients with
haemorrhagic strokes. 
The benefit extended to other major vascular events
also, with fewer total major coronary events in the active arm
[26% relative risk reduction; 95% CI 6-42], and fewer non fatal
strokes and non fatal myocardial infarction in the active arm.
However, there was no significant difference in the two arms
with respect to all cause mortality and vascular mortality.
597 J Pak Med Assoc
Evidence Based Medicine
Effects of a perindopril-based blood-pressure-lowering regimen
in patients with previous stroke or transient ischaemic attack (progress).
How do the results affect practice in Pakistan?
Maria Khan, Ayeesha Kamran Kamal
Director Stroke Service and Vascular Fellowship Program, Aga Khan University Hospital, Karachi, Pakistan.
Among participants who received the combination
therapy, the reduction in blood pressure was more (mean 12/5
mmHg), and the stroke risk was also significantly lower when
compared to double placebo. This was observed for all stroke
subtypes, and for total major coronary events, and for non fatal
stroke, non fatal MI and vascular death. These differences were
not as pronounced when single agent was compared to
placebo.
Another important outcome of this study was that
active treatment with either perindopril alone or its
combination with Indapamide, conferred similar advantages
in both hypertensive and non-hypertensive individuals.
Hypertension was defined as systolic blood pressure >160
mm Hg or diastolic blood pressure >90 mm Hg at baseline).
What were the conclusions?
The authors concluded that the study treatment was
shown to be safe and effective across a broad range of patients,
irrespective of their baseline blood pressures and the type of
their initial stroke. The results suggest that 5 years' treatment
with the combination of perindopril and Indapamide would
have resulted in the avoidance of one fatal or major non-fatal
vascular event among every 11 patients (95% CI 9-16).
Is this study relevant to clinical practioners
within Pakistan?
A National Health Survey conducted during early 90s
in Pakistan revealed that 33% of the population above age of
45 has hypertension. Hypertension is the single most important
modifiable risk factors for both ischaemic and haemorrhagic
strokes and it would be much more prevalent in this group of
individuals. In contrast to developed countries a greater
proportion of patients in Pakistan has hypertensive ICH -
where according to this study the benefit of treatment is
maximal. It appears that the degree of reduction in blood
pressure impacts a favourable outcome. Whether additional
drug class specific pleiotropic effects also benefit the patient is
unknown.
With the kind of impact reported with blood pressure
lowering in this study, all patients with history of stroke or TIA
should be put on anti-hypertensives. The amount of risk
reduction is in fact more than what can be achieved with
antiplatelets like aspirin. Also the benefit is seen across all
stroke subtypes, which means that this is one treatment that can
be instituted without the need for neuroimaging which in many
parts of Pakistan is still not feasible. However, it should be
made very clear that these are chronic stable stroke patients
where there is no evidence to support risk of stroke progression
by lowering blood pressure. 
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